The U.S. Food and Drug Administration (FDA) has given priority review to the antipsychotic med Abilify for the treatment of pediatric schizophrenia. The FDA made this move after Abilify was found effective in treating pediatric schizophrenia patients (ages 13 years to 17 years) in recent international studies. Priority review status is granted when the FDA intends to make a decision on the supplemental use of the med within six months.
Read moreSchizophrenic mothers and fathers are twice as likely to have a child diagnosed with autism. These are the findings from a study... Read more »
Source: ADAM Encyclopedia
Schizophrenia is categorized as a brain disease, not a psychological disorder, Drug treatment is the primary therapy. Studies indicate, however, that... Read more »
A mother writes that her son, who has been diagnosed with schizophrenia, stops taking his Risperdal when he is feeling better. She then has... Read more »
U.S. researchers say they've spotted a gene variant that may raise the risk of schizophrenia in some people, a finding that may lead to new... Read more »
Large, rare structural changes in DNA called copy number variants may play a role in schizophrenia, according to U.S. researchers, who said their... Read more »
Psychiatrist Ronald Pies talks about the laws surrounding schizophrenia and driving. Pies discusses this issue by sharing the story of Harry, a... Read more »